NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company
NeuroBo Pharmaceuticals, a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]
BIO89-100 NASH clinical trial : US-based biopharma company 89Bio has initiated a proof of concept phase 1b/2a clinical trial for BIO89-100, its NASH drug in development, by screening the first patients. The proof of concept trial will evaluate the glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in patients with nonalcoholic steatohepatitis (NASH) or patients […]
Continue reading …
Business News Today
- AGC Networks acquires communications technology firm Pyrios
- Manna Pro Products acquires online pet brand Doggie Dailies
- MedCrypt acquires medical device cybersecurity software firm MedISAO
- Improving acquires custom software development firm Object Partners
- High Street Insurance acquires Michigan-based Capital Insurance Group
- Mill Creek Residential breaks ground on Modera Washington in Houston
- Cincinnati-based RIA Lenox Wealth Management acquired by Creative Planning
- Jersey Elevator acquired by Arcline Investment Management
- U.S. Gold acquires Northern Panther Resource, owner of Challis gold project
- Perrigo acquires skincare and hair loss treatment brands from Sanofi
